Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry
Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which high-risk women are likely to be using endocrine ris...
Guardado en:
Autores principales: | Yash S. Huilgol, Holly Keane, Yiwey Shieh, Robert A. Hiatt, Jeffrey A. Tice, Lisa Madlensky, Leah Sabacan, Allison Stover Fiscalini, Elad Ziv, Irene Acerbi, Mandy Che, Hoda Anton-Culver, Alexander D. Borowsky, Sharon Hunt, Arash Naeim, Barbara A. Parker, Laura J. van ‘T Veer, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial
por: Holly Keane, et al.
Publicado: (2021) -
Athena in the World of Techne: The Gender Dimension of Technology, Innovation and Entrepreneurship
por: Ranga,Marina, et al.
Publicado: (2010) -
Back to the Future: Sparta, Athena, and the battle for the Arab public sphere
por: Tarek Cherkaoui
Publicado: (2017) -
Certifying Gender Equality in Research: Lessons Learnt From Athena SWAN and Total E-Quality Award Schemes
por: Charikleia Tzanakou, et al.
Publicado: (2021) -
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Mark Jesus M. Magbanua, et al.
Publicado: (2021)